Photomicrograph of a Nerium oleander leaf.
Nerium oleander cultivation.
Photomicrograph of human nerve cells.

Phoenix Biotechnology, Inc. (PBI)'s Focus

Phoenix Biotechnology, Inc., has been exploring the health-related benefits of a novel extract of Nerium oleander for the past 20 years. The company has developed a supercritical CO2 extraction of Nerium oleander into a new botanical drug – PBI-05204.

PBI-05204 is a ‘botanical drug’ that has been through initial FDA review and approved for the Phase I and Phase II clinical trials which were conducted in the United States. These trials have shown that this oral (capsule) formulation is safe for administration to patients without undue toxicity.

A distinction of PBI-05204 is that research has consistently proven that this drug crosses the blood brain barrier which opens up several potential applications. Extensive research has been done in the following areas: Antiviral, Cancer, and Neurodegenerative Diseases.


June, 2021
Antiviral effects of oleandrin". Letter to the editor of the Journal of the American College of Emergency Physicians. Newman, R. and Jagannadha Sastry, K. (2021). JACEP Open, 2: e12469.
Our recent research with oleandrin as a proposed inhibitor of SARS-CoV-2 has demonstrated that low nanomolar concentrations of this molecule achieved near-total inhibition of the relative infectivity of this virus. The effective antiviral oleandrin concentrations were a fraction of that required for the control of cancer cell lines. This suggests that the use of oleandrin or a properly defined extract containing this molecule could be used to control COVID-19 without toxicity.


March, 2021
Antiviral activity of oleandrin and a defined extract of Nerium oleander against SARS-CoV-2". Biomedicine & Pharmacotherapy.
With continued expansion of COVID-19 caused by the severe respiratory syndrome 2 (SARS-CoV-2) antiviral therapies as well as effective vaccines are desperately needed. This article presents evidence for the significant inhibition of SARS-CoV-2 by oleandrin and the company's experimental product PBI-06150.